GLOW70
An advanced regenerative research blend combining GHK-Cu 50 mg, BPC-157 10 mg and TB-500 10 mg to investigate extracellular-matrix remodelling, angiogenic signalling, tissue protection and cellular migration within one fixed formulation.
GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg. The selector describes the vial format and must not be interpreted as a dose.
Interested in this compound?
Contact the PHONYX team for availability and catalogue information.
What is GLOW70?
GLOW70 is a fixed 70 mg research blend containing three regenerative peptides in a 50:10:10 mass ratio. GHK-Cu contributes copper-dependent extracellular-matrix and gene-signalling research; BPC-157 contributes cytoprotective, vascular and fibroblast-related pathways; TB-500 contributes actin-associated cellular migration and tissue-remodelling research.
The formulation is investigated as a combined model for skin and connective-tissue biology, recovery after experimental stress, collagen and elastin organization, angiogenic signalling, wound repair and functional tissue remodelling.
Three complementary regenerative pathways
GHK-Cu — matrix signalling
GHK-Cu is researched for copper transport, collagen and elastin production, glycosaminoglycan synthesis, extracellular-matrix remodelling and modulation of inflammatory and oxidative pathways.
BPC-157 — tissue protection
BPC-157 is associated with VEGF/VEGFR2 and nitric-oxide signalling, fibroblast migration, angiogenesis, gastrointestinal cytoprotection and connective-tissue repair models.
TB-500 — cellular migration
TB-500-related research focuses on actin dynamics, cell migration, cytoskeletal organization, tissue remodelling and recovery-associated mobility.
Contribution of each component
| Component | Amount | Primary research role | Selected pathways |
|---|---|---|---|
| GHK-Cu | 50 mg | Matrix and skin biology | Collagen, elastin, copper enzymes |
| BPC-157 | 10 mg | Cytoprotection and angiogenesis | VEGFR2, NO, fibroblasts |
| TB-500 | 10 mg | Cell migration and remodelling | Actin and cytoskeleton |
Research applications of the component pathways
Skin biology Matrix renewal and appearance-related research
GHK-Cu-related evidence supports research into collagen, elastin, glycosaminoglycans and dermal matrix organization, while the additional components contribute tissue-protection and cell-migration pathways.
Wound models Repair and tissue closure
The three components are associated with fibroblast activity, angiogenic signalling, cellular movement and remodelling of damaged tissue.
Musculoskeletal Tendon, ligament and muscle research
BPC-157 and TB-500 pathways are frequently investigated in experimental connective-tissue and recovery models, while GHK-Cu contributes matrix-remodelling biology.
Hair and follicles Scalp and follicular research
GHK-Cu has been studied in relation to hair-follicle support and dermal matrix maintenance; combination-specific controlled evidence remains limited.
Evidence limitation Fixed-blend research
Most published evidence concerns the individual components or their biological pathways. Controlled human evidence for the exact 70 mg fixed blend is not established.
GLOW70 protocol formats reported for the fixed blend
Standard regenerative
3.5 mg total blend, once daily, for 4–8 weeks, followed by approximately 4 weeks off.
Skin revitalization
7 mg total blend, every other day, for 8–12 weeks, followed by approximately 8 weeks off.
Fixed-ratio interpretation
Every measured amount preserves the formulation ratio of 50 parts GHK-Cu to 10 parts BPC-157 to 10 parts TB-500.
| Research protocol | Total blend amount | Approximate component amounts | Frequency | Active period | Break |
|---|---|---|---|---|---|
| Standard regenerative | 3.5 mg | 2.5 mg GHK-Cu + 0.5 mg BPC-157 + 0.5 mg TB-500 | Once daily | 4–8 weeks | Approximately 4 weeks |
| Skin revitalization | 7 mg | 5 mg GHK-Cu + 1 mg BPC-157 + 1 mg TB-500 | Every other day | 8–12 weeks | Approximately 8 weeks |
Outcomes associated with the combined pathways
Collagen and elastin
GHK-Cu-related research describes support for extracellular-matrix synthesis and organization.
Angiogenic signalling
BPC-157-related models examine VEGF, nitric oxide and local vascular support.
Repair-associated cells
TB-500-related pathways are linked to actin regulation and cellular movement.
Connective-tissue models
The blend brings these pathways together for broader regenerative research designs.
The rationale for GLOW70 is mechanistic complementarity. Evidence for the individual components does not automatically establish the efficacy or safety of the fixed blend.
Component-specific and combination-related uncertainties
Potential observations described in research-oriented sources include transient local discomfort, redness or sensitivity. Controlled human safety data for the exact fixed blend remain limited.
Unresolved issues include systemic copper exposure, angiogenesis-related risks, immunogenicity, interactions between the three components and long-term effects. Identity, purity, sterility and endotoxin burden remain essential laboratory quality considerations.
A fixed blend with three distinct biological profiles
GHK-Cu, BPC-157 and TB-500 differ in sequence, molecular properties and biological persistence. The fixed mass ratio ensures consistent composition but does not imply equal half-lives, distribution or target engagement.
PHONYX portfolio format
Evidence behind the component mechanisms
Frequently asked questions
What does GLOW70 contain?
GHK-Cu 50 mg, BPC-157 10 mg and TB-500 10 mg, for 70 mg total material.
Why are the three peptides combined?
The blend joins extracellular-matrix, angiogenic, cytoprotective and cellular-migration pathways within one research formulation.
What protocol is used for standard regenerative research?
The requested source describes 3.5 mg total blend once daily for four to eight weeks, followed by approximately four weeks off.
What protocol is used for skin-revitalization research?
The requested source describes 7 mg total blend every other day for eight to twelve weeks, followed by approximately eight weeks off.
How much of each component is present in 3.5 mg?
Approximately 2.5 mg GHK-Cu, 0.5 mg BPC-157 and 0.5 mg TB-500.
How much of each component is present in 7 mg?
Approximately 5 mg GHK-Cu, 1 mg BPC-157 and 1 mg TB-500.
Is 70 mg a single administration?
No. It is the total lyophilized content of the vial.
Is GLOW70 clinically approved?
No. The fixed blend is not an approved medicinal product.
How is reconstituted material stored?
Research-oriented product information generally describes refrigerated storage at 2–8°C under controlled conditions.
Does evidence for each peptide prove the blend works?
No. Component evidence does not automatically establish the safety or efficacy of the fixed combination.
Research Disclaimer
This compound is presented exclusively for laboratory and scientific research. It is not intended for human consumption, self-administration, diagnostic use, treatment, cure or prevention of disease. Information describing research protocols is provided solely for documentary and educational context and must not be interpreted as medical advice, a dosing recommendation or instructions for use. GLOW70 is not an approved medicinal product, and its clinical safety and efficacy remain unestablished.